Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2011. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding an increase in their personal holdings of Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on shareholding changes resulting from a dividend reinvestment plan.
Material Changes
The material change reported is an increase in share ownership by specific individuals following the reinvestment of the dividend paid to shareholders on January 6, 2011. The transaction price was £12.53 per Ordinary share. The specific increases in holdings are as follows:
- Mr A P Witty: 813 shares
- Mrs C M Witty: 727 shares
- Mr J S Heslop: 566 shares
- Dr D Pulman: 342 shares
- Mrs C R Pulman: 70 shares
- Mr I W Whyte: 49 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The notification was made in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Dividend reinvestment occurred on January 6, 2011, at a price of £12.53 per share.
- Directors and connected persons increased their holdings as detailed in the transaction list.
- The notification was advised to the Company and the named persons on January 12, 2011.
- This filing contains no financial performance data for the period.